Novavax (NVAX -1.98%) is a leading vaccine maker that has already won authorizations in many countries worldwide. In this Motley Fool Live segment from "The Pharma & Biotech Show," recorded on March 23, Fool.com contributors Taylor Carmichael and Keith Speights discuss why they're bullish on Novavax now.
10 stocks we like better than Novavax
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Novavax wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of April 7, 2022
Taylor Carmichael: I do think over time, conservative, cautious people who are worried about disease, worried about the illness, who like to vaccinate, will vaccinate. I think a combo vaccine is very important, which we've talked about multiple times. I remain very bullish on Novavax. I'm very bullish on this entire sector mainly because it's so cheap, given how much money they're making and how big the opportunity is over the next decade. COVID is not going away. These guys are the leaders, they've already made a huge amount of money and they are P's of one and two. It's just crazy.
Keith Speights: My personal take is Novavax is probably going to win FDA authorization relatively soon, when that happens, I don't know, but relatively. Look, it's clinical data solid. The company has already won authorizations in a lot of other countries, the EU, Great Britain, Canada, Australia, India, South Korea, and that's just a few, there's more. I think we could see a slow uptake in the US like Novavax's seeing in Germany, though I think that there's some similar dynamics, but I think the companies ultimate prospects, it's real fortunes hinge on, first, getting authorization as a booster to other vaccines, so the [inaudible]. Then the development of its COVID/flu combo that you mentioned. I think that's going to be where Novavax can really succeed.